Nasdaq:QTRX
Quanterix Corp
A pioneer in ultra-sensitive multiplexed immunoassays enabling early disease detection via advanced Simoa technology.
Key Metrics
Investment Thesis
Bull Case
Investors may view QTRX as a high-potential biotech play with a transformative platform that could redefine early disease detection standards in neuroscience and cardiology. The expanding addressable market for precision diagnostics, combined with the company's technological superiority in sensitivity, offers substantial upside if key product launches achieve commercial traction.
Bear Case
The sustained net losses over three consecutive years and negative operating cash flow raise concerns about the company's ability to fund operations without dilutive financing or strategic partnerships. With a significant retained earnings deficit of $470M and limited current cash reserves, the path to profitability remains uncertain in a capital-constrained environment.
About Quanterix Corp
Quanterix Corp (QTRX) is a premier provider of ultra-sensitive multiplexed immunoassays designed to detect biological markers of disease in the blood. The company serves hospitals and clinical laboratories globally with its proprietary Simoa technology, which enables early detection of conditions like Alzheimer's and heart failure through minimal sample volumes. Its product portfolio focuses on neuroscience, cardiovascular health, and oncology applications where high sensitivity is critical for patient outcomes.
Analysis
Management Discussion
While revenue grew steadily from $105.5M in 2022 to $137.4M in 2024, the company continues to operate at a significant net loss of $38.5M, reflecting heavy investments in R&D and commercial expansion. Cash flow from operations turned negative while cash flow from financing remained minimal, indicating reliance on existing reserves rather than external capital inflows to fund growth.
Industry Overview
The global diagnostic testing industry is rapidly evolving towards precision medicine, driven by an aging population and advances in biomarker science that enable earlier intervention. Quanterix operates at the intersection of biotechnology and healthcare services, targeting high-value niches where early detection significantly improves patient survival rates and reduces long-term treatment costs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $105.5M | $122.4M | $137.4M |
| Cost of Revenue | $58.7M | $51.7M | $54.3M |
| Gross Profit | $46.8M | $70.6M | $83.1M |
| Operating Expenses | $148.5M | $120.3M | $135.7M |
| Operating Income | $-101.7M | $-49.7M | $-52.6M |
| R&D | $25.9M | $24.9M | $31.1M |
| G&A | $92.0M | $90.2M | $101.6M |
| Stock-Based Comp | $15.4M | $16.8M | $20.0M |
| Depreciation | $3.5M | $4.7M | $4.8M |
| Amortization | $1.8M | $1.6M | $1.6M |
| Other OpEx | $30.6M | $5.2M | $3.0M |
| Non-Operating Income | $5.1M | $18.1M | $14.5M |
| Pre-Tax Income | $-96.6M | $-31.6M | $-38.1M |
| Income Tax | $65.0K | $719.0K | $434.0K |
| Continuing Ops | $-96.7M | $-32.3M | $-38.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-96.7M | $-32.3M | $-38.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-96.7M | $-32.3M | $-38.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $381.4M | $378.4M | $363.6M |
| Cash & Equivalents | $338.7M | $174.4M | $56.7M |
| Marketable Securities | — | $6.9M | $0 |
| Accounts Receivable | $19.0M | $25.4M | $32.1M |
| Inventory | $16.8M | $22.4M | $32.8M |
| Prepaid Expenses | $6.9M | $9.3M | $9.6M |
| Other Current Assets | $0 | $140.0M | $232.4M |
| Long-Term Assets | $52.8M | $46.6M | $42.9M |
| PP&E (Net) | $20.2M | $17.9M | $17.1M |
| Intangibles | $7.5M | $6.0M | $4.0M |
| Goodwill | — | $0 | — |
| Operating Leases | $21.2M | $18.3M | $16.3M |
| Other LT Assets | $3.9M | $4.4M | $5.4M |
| Total Assets | $434.2M | $425.0M | $406.5M |
| Current Liabilities | $31.0M | $38.5M | $42.0M |
| Accounts Payable | $3.8M | $5.0M | $7.0M |
| Current Leases | $2.7M | $4.2M | $4.8M |
| Deferred Revenue | $8.6M | $9.5M | $8.8M |
| Other Current Liab | $15.8M | $19.7M | $21.5M |
| Long-Term Liabilities | $44.3M | $39.6M | $34.5M |
| LT Operating Leases | $41.4M | $37.2M | $32.6M |
| Other LT Liab | $1.5M | $1.2M | $800.0K |
| Total Liabilities | $75.3M | $78.1M | $76.5M |
| Shareholders' Equity | $358.9M | $346.9M | $330.0M |
| Retained Earnings | $-402.2M | $-434.5M | $-470.1M |
| AOCI | $-2.6M | $-1.8M | $-3.1M |
| Total L&E | $434.2M | $425.0M | $406.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-96.7M | $-32.3M | $-38.5M |
| Non-Cash Adjustments | $64.2M | $-7.8M | $-14.0M |
| Working Capital Changes | $-15.8M | $21.3M | $17.4M |
| Cash from Operations | $-48.3M | $-18.9M | $-35.2M |
| Capital Expenditures | $11.7M | $3.8M | $3.4M |
| Cash from Investing | $-11.2M | $-148.4M | $-82.3M |
| Cash from Financing | $2.3M | $2.7M | $456.0K |
| FX Effect | $-538.0K | $301.0K | $-734.0K |
| Net Change in Cash | $-57.2M | $-164.6M | $-117.0M |
| Beginning Cash | $399.0M | $341.3M | $177.0M |
| Ending Cash | $341.3M | $177.0M | $59.3M |
Frequently Asked Questions
How does Quanterix Corp make money?
Revenue is primarily driven by the sale of its proprietary Simoa platform instruments and reagent kits for neuroscience, cardiovascular, and oncology diagnostics, with growing adoption in clinical laboratories worldwide.
What are the main risks for QTRX?
The company faces significant risks from high cash burn rates exceeding $35M annually without current profitability, creating pressure on its substantial cash reserves. Regulatory approval delays or reimbursement challenges in key markets could severely impact the commercialization timeline for new biomarker applications. Intense competition from established diagnostic giants and potential patent expirations pose threats to long-term market share and pricing power.
What is QTRX's competitive advantage?
The company's ultra-sensitive Simoa technology allows for the detection of disease markers at levels significantly lower than current industry standards, providing a critical moat in early diagnosis markets. Its multiplexing capability enables simultaneous testing of multiple biomarkers from a single small blood sample, enhancing diagnostic efficiency and cost-effectiveness for labs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.